Interstitial Cystitis / Bladder Pain Syndrome (Investigational)
Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for interstitial cystitis / bladder pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is highly investigational.
- ¿Qué evidencia existe?
- Tier C (highly investigational). Only isolated case reports describe sacral / suprapubic application; there are no randomized controlled trials. Evidence-based management per AUA 2022 guideline is stepwise: behavioral modifications and dietary trigger avoidance, oral pentosan polysulfate (PPS) and amitriptyline, intravesical DMSO or heparin instillations, hydrodistention with cystoscopy, sacral neuromodulation, and selective cyclosporine A for refractory cases. Bladder ulcers (Hunner lesions) benefit from fulguration or triamcinolone injection.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the lower abdomen and sacrum for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Severe allergic reaction in mast-cell-activation prone patients
- Worsening of bladder pain in the first 24 hours
- Small permanent scars at bite sites
- Delay of cystoscopy that could identify Hunner lesions or rule out bladder malignancy
- Delay or replacement of evidence-based AUA-stepwise therapy
- Quién no debería considerar esto
- Patients with active urinary tract infection
- Patients in whom bladder malignancy has not been ruled out by cystoscopy
- Patients with mast cell activation syndrome with anaphylaxis history
- Patients within 2 weeks of intravesical therapy
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not engaged with first- and second-line AUA-stepwise therapy
- Qué preguntar a su clínico
- Has my IC/BPS diagnosis been confirmed (excluded UTI, evaluated for Hunner lesions on cystoscopy if appropriate)?
- Have I tried behavioral modification, dietary trigger avoidance, and oral PPS or amitriptyline?
- Have I been offered intravesical DMSO or heparin instillations?
- Am I a candidate for hydrodistention, sacral neuromodulation, or cyclosporine A?
- If I have Hunner lesions, have they been fulgurated or injected with triamcinolone?
- Has the practitioner explained that NO intravesical or genital placement is permitted?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Cuándo buscar atención urgente
- New visible blood in urine (especially clots) or unexplained urinary bleeding
- Inability to urinate (acute retention)
- Severe pelvic pain with fever, chills (possible UTI, pyelonephritis, or PID)
- Severe nausea, vomiting, flank pain (possible obstruction or stone)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty (heightened concern in mast-cell-prone patients)
Qué NO significa esto
- This is not FDA-cleared for IC/BPS.
- Isolated case reports do NOT establish efficacy versus AUA-stepwise therapy.
- Mechanism rationale (neurogenic modulation, anti-inflammation) does NOT address urothelial barrier dysfunction or mast-cell-related inflammation.
- Leech therapy is NEVER intravesical or genital — those placements are absolutely contraindicated.
- Leech therapy is not a substitute for behavioral modification, oral PPS / amitriptyline, intravesical instillations, or hydrodistention with cystoscopy.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- urogenital
- ICD-10
- N30.10, N30.11
- Safety tier
- high
Evidence Summary
Interstitial cystitis/bladder pain syndrome is managed per the AUA 2022 guideline as stepwise multimodal therapy: behavioral modification, oral pentosan polysulfate and amitriptyline, intravesical DMSO or heparin, hydrodistention, sacral neuromodulation, and selective cyclosporine for refractory cases. No controlled clinical trial of leech therapy for interstitial cystitis/bladder pain syndrome has been published; use is investigational and mechanistic only, and the honest evidence grade is D. The complex urothelial-barrier dysfunction and mast-cell-related neurogenic inflammation underlying IC/BPS is unlikely to be directly addressed by peripheral leech application, and any antiinflammatory or neurogenic-modulation rationale remains theoretical.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active urinary tract infection
- Bladder malignancy (cystoscopy required for diagnosis)
- Recent intravesical therapy (<2 weeks)
- Mast cell activation syndrome with anaphylaxis history
Related Conditions
Peyronie's Disease (Stable Phase)
Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)
Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.
Peyronie's Disease (Extended Investigational Adjunct)
Highly investigational extended-protocol adjunct for stable Peyronie's disease; case reports only; collagenase clostridium histolyticum and surgical correction remain primary.